{"id":"W4415871235","doi":"10.1136/jitc-2025-sitc2025.1305","title":"1305 Coformulation of favezelimab and pembrolizumab as neoadjuvant therapy for resectable cutaneous squamous cell carcinoma (cSCC): Results from cohort a of the phase 2 keyform-010 study","year":2025,"lang":"","type":"article","venue":"","topic":"Nonmelanoma Skin Cancer Studies","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"McGill University; Jewish General Hospital; Centre hospitalier universitaire de Québec","funders":"","keywords":"Pembrolizumab; Cohort; Neoadjuvant therapy; Basal cell; Cohort study; Chemotherapy; Carcinoma","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001867562,0.0004405439,0.0009340068,0.0002778026,0.0002376215,0.0007334611,0.0002698121,0.0004315359,0.004781628],"category_scores_gemma":[0.001845249,0.0002573821,0.001652411,0.000344641,0.0002052212,0.0005593802,0.0002153418,0.001082854,0.0007119027],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.000642211,"about_ca_system_score_gemma":0.0007312622,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0008537108,"about_ca_topic_score_gemma":0.003604243,"domain_scores_codex":[0.9993506,0.0003390303,0.00006000607,0.00008512039,0.00009698071,0.00006827819],"domain_scores_gemma":[0.9992012,0.0002613635,0.0002086792,0.00008613076,0.00009033255,0.0001523143],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.6120489,0.01020696,0.04140044,0.003830324,0.01731811,0.0002031153,0.0001911472,0.001394963,0.02037373,0.0004520503,0.02151376,0.2710665],"study_design_scores_gemma":[0.3584375,0.3804591,0.192281,0.0007975817,0.01384387,0.001011181,0.0002564886,0.001810631,0.008483991,0.00062489,0.04191644,0.00007725489],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9629034,0.01699173,0.0008714837,0.0006620023,0.000442642,0.002295191,0.007154532,0.00007991996,0.008599202],"genre_scores_gemma":[0.9816868,0.004876187,0.001159999,0.0008010394,0.0002085565,0.001312811,0.006119247,0.00002574866,0.003809561],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.004781628,"threshold_uncertainty_score":0.01599616,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.01525870662163638,"score_gpt":0.3050002982557685,"score_spread":0.2897415916341322,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}